• Nine abstracts ready for the SfN conference in November.
  • Joined-up preclinical and clinical trials to advance psilocybin drug development
  • Transpharmation joins HaPpY team to help break the vicious cycle of chronic pain & mood disorders, see News for details
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • New state-of-the-art premises at Discovery Park, Kent
 

Schizopherenia

Browse our range of publications
Filters
List of articles in category Schizophrenia
Publications
The effect of the second generation of antipsychotic risperidone on aggressive behaviour in male CD-1 mice :
Register to read more ...
The NMDAr positive allosteric modulator CAD-8688 reverses mismatch negativity impairments in the rat sub-chronic PCP model of schizophrenia :
Register to read more ...
Mismatch Negativity in rats –A translational model in schizophrenia research :
Register to read more ...
The NMDA Receptor Antagonist Ketamine Exerts Biphasic Effects on Mismatch Negativity in the Rat :
Register to read more ...
 
  • You are here:  
  • Home
  • Schizophrenia

Our clients are our partners.
We work hard around the globe to create breakthrough results for them.

Start a Conversation

preclinical +44 (0)203 633 2807

clinical trials +353 (0)1896 42 60

clinical research +48 515 244 120

EEG contact@transpharmation.co.uk

Copyright ©2021 Transpharmation Ltd. Website created by Identity Ipswich Web Design